A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).

  • Roberts, Stuart (Primary Chief Investigator (PCI))
  • Lewis, Paula (Project Manager)

Project: Research

StatusActive
Effective start/end date24/01/1930/04/23